Merck announces exceptional hepatitis C therapy study results
The treatment regimen of 100mg of grazoprevir and 50 mg of elbasvir requires daily doses. The study involved treatment-naïve patients as well as other patients who did not succeed with prior pegylated interferon HCV therapy. All of the patients enrolled in the study had CKD in Stage 4 or 5.
Twelve weeks after finishing the treatments, 115 of the 116 patients (or 99 percent) showed sustained virologic responses.
“There is an unmet medical need to treat chronic hepatitis C virus infection in patients with advanced chronic kidney disease,” Houston Methodist Hospital Chief of Hepatology Howard Monsour said. “In this trial, the first to investigate an all-oral ribavirin-free treatment regimen in treatment-naïve and treatment-experienced CKD patients, treatment with grazoprevir and elbasvir for 12 weeks was effective in this study population with HCV genotype 1 infection.”
Merck officials have presented this material at The International Liver Congress 2015, which is part of the 50th annual congress of the European Association for the Study of the Liver.